PHOTO
Manama, AGU: A study conducted at Al Jawhara bint Ebraheem Centre for Molecular Medicine, Genetics and Inherited Disorders (ACMID) of the Arabian Gulf University (AGU) was published on the cover page of a prestigious scientific journal recently.
The study, which addressed Covid-19 targeted managements and vaccine development, was conducted by ACMID Director Dr Moiz Bakhiet and ACMID Faculty Member Dr Sebastien Taurin, and it was published on the cover page of the latest edition of Cytokine and Growth Factor Reviews.
The Journal's cover page showed an illustrative image of the study, explaining the journey of the virus from its entry into the body and its encounter with primary immune cells in the mucous membranes, until it reaches lung cells and phagocytes defending them, and its transcription and reproduction processes inside the cell through the stages of its life cycle in the human body.
The image also illustrates the confrontation that occurs between the virus and the immune proteins and cells, in addition to the resulting cytokine storm and its effect on the lungs and on the course of blood clotting processes, and the formation of small clots that harm the body's tissues and various organs.
Through the image, it is clarified, in a simplified manner, how scientists have directed their efforts towards fighting the virus at every stage during these challenges and the types of drugs used as weapons to stop the virus replication processes inside the cell and the formation of its proteins, as well as the process of its reproduction and spreading.
The results shown in the image were reached through research and clinical studies that have been conducted to come up with the traditional vaccines and the next generation smart vaccines.
In general, the study included various illustrations and dealt at length and in precise detail with all of these stages and contained 174 modern scientific references for all that scientists have done since the announcement of the discovery of the novel Coronavirus in these fields.
-Ends-
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
